IN2015DN03734A - - Google Patents
Download PDFInfo
- Publication number
- IN2015DN03734A IN2015DN03734A IN3734DEN2015A IN2015DN03734A IN 2015DN03734 A IN2015DN03734 A IN 2015DN03734A IN 3734DEN2015 A IN3734DEN2015 A IN 3734DEN2015A IN 2015DN03734 A IN2015DN03734 A IN 2015DN03734A
- Authority
- IN
- India
- Prior art keywords
- treatment
- compound
- pharmaceutically acceptable
- acceptable salt
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| PCT/US2013/062964 WO2014055588A1 (fr) | 2012-10-05 | 2013-10-02 | Traitement de la maladie d'alzheimer légère à modérée |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN03734A true IN2015DN03734A (fr) | 2015-09-18 |
Family
ID=49354960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN3734DEN2015 IN2015DN03734A (fr) | 2012-10-05 | 2013-10-02 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (fr) |
| JP (2) | JP6566868B2 (fr) |
| KR (1) | KR20150064743A (fr) |
| CN (2) | CN104703592A (fr) |
| AU (2) | AU2013327450B2 (fr) |
| BR (1) | BR112015007641A8 (fr) |
| CA (1) | CA2886785C (fr) |
| EA (1) | EA201590687A1 (fr) |
| HK (1) | HK1207004A1 (fr) |
| IL (1) | IL237730B (fr) |
| IN (1) | IN2015DN03734A (fr) |
| MX (1) | MX2015003732A (fr) |
| NZ (2) | NZ739521A (fr) |
| SG (2) | SG10201702648YA (fr) |
| WO (1) | WO2014055588A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190823A1 (fr) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Sels pharmaceutiquement acceptables de [3-(4- {2-butyl-1-[4-(4-chlorophénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine |
| WO2019190822A1 (fr) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Formes cristallines de [3-(4- {2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl} -phénoxy)-propyl]-diéthyl-amine |
| EP3864008A1 (fr) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Métabolites de [3-(4-{2-butyl-1-[4-(4-chloro-phénoxy)-phényl]-1h-imidazol-4-yl}-phénoxy)-propyl]-diéthyl-amine |
| WO2020086388A1 (fr) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Compositions d'activateur de glucokinase destinées au traitement d'une déficience cognitive |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114716551B (zh) * | 2021-11-12 | 2023-01-24 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2373875T3 (es) * | 2002-03-05 | 2012-02-09 | Transtech Pharma, Inc. | Derivados de azol mono y bicíclicos que inhiben la interacción de ligandos con rage. |
| AU2004251599A1 (en) * | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| EP1707203A1 (fr) * | 2005-04-01 | 2006-10-04 | Bioprojet | Utilization des allkylamines sans imidazoles comme ligandes du recepteur histamine H3 pour le traitement de la maladie de Parkinson, de l'apnee obstructive du sommeil, de la demence vasculaire et de la demence avec corps de Lewy |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| WO2008153957A1 (fr) * | 2007-06-07 | 2008-12-18 | The Trustees Of Columbia University In The City Of New York | Utilisation d'antagonistes de rage pour le traitement de l'obésité et de maladies associées |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| EP2638052B1 (fr) * | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Inhibiteurs sélectifs de glycosidase et utilisations de ceux-ci |
-
2013
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 MX MX2015003732A patent/MX2015003732A/es active IP Right Grant
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/fr active Application Filing
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/fr not_active Withdrawn
- 2013-10-02 CA CA2886785A patent/CA2886785C/fr active Active
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Application Discontinuation
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
- 2015-08-11 HK HK15107776.8A patent/HK1207004A1/xx unknown
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013327450B2 (en) | 2018-07-12 |
| BR112015007641A2 (pt) | 2017-07-04 |
| JP2015535850A (ja) | 2015-12-17 |
| HK1207004A1 (en) | 2016-01-22 |
| EA201590687A1 (ru) | 2015-09-30 |
| IL237730B (en) | 2018-10-31 |
| CN110292638A (zh) | 2019-10-01 |
| AU2018203434A1 (en) | 2018-06-07 |
| NZ705813A (en) | 2018-02-23 |
| CA2886785A1 (fr) | 2014-04-10 |
| JP6566868B2 (ja) | 2019-08-28 |
| CN104703592A (zh) | 2015-06-10 |
| AU2013327450A1 (en) | 2015-05-14 |
| JP6894940B2 (ja) | 2021-06-30 |
| CA2886785C (fr) | 2022-06-07 |
| SG10201702648YA (en) | 2017-04-27 |
| MX2015003732A (es) | 2015-09-23 |
| NZ739521A (en) | 2019-06-28 |
| EP2903606A1 (fr) | 2015-08-12 |
| JP2019163301A (ja) | 2019-09-26 |
| BR112015007641A8 (pt) | 2018-04-03 |
| WO2014055588A1 (fr) | 2014-04-10 |
| SG11201502210VA (en) | 2015-04-29 |
| KR20150064743A (ko) | 2015-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| WO2015031564A3 (fr) | Composés de la série des 1h-benzo[d]imidazoles substitués à titre d'inhibiteurs de déméthylase 1 spécifique de la lysine (lsd1) | |
| IN2015DN03734A (fr) | ||
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| MX2014003080A (es) | Inhibidores sustituidos de n-[1-ciano-2- (fenil) etil]-2-azabiciclo[2.2.1] heptan-3-carboxamida de catepsina c. | |
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| PH12015501661B1 (en) | Pyridone amides as modulators of sodium channels | |
| IN2014DN10386A (fr) | ||
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| IN2014KN00948A (fr) | ||
| GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MD20140072A2 (ro) | Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| JO3459B1 (ar) | تركيبات صيدلانية لعلاج مرض الزهايمر | |
| MX2013005407A (es) | 5-halopirazolcarboxamidas. | |
| TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
| GEP20186892B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
| MD20140073A2 (en) | New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them | |
| IN2015DN01119A (fr) | ||
| MX2014004196A (es) | Citramida de rasagilina. | |
| PH12015501398A1 (en) | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity | |
| UA110128C2 (uk) | Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди | |
| ZA201500362B (en) | Novel compound having ability to inhibit 11b-hsd1 enzyme or pharmaceutically acceptable salt thereof, method for producing same, and pharmaceutical composition containing same as active ingredient | |
| MX2013005258A (es) | N-aril pirazol(tio)carboxamidas. | |
| MX2014013664A (es) | N-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxietil)ami no)-2-oxo-n-fenil-1,2-dihidroquinolin-3-carboxamida. |